Cullinan Oncology to Participate in Upcoming Virtual Healthcare Conferences
April 05 2022 - 8:00AM
Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”) a
biopharmaceutical company focused on developing a diversified
pipeline of targeted therapies for patients with cancer, today
announced that its management team will participate in the
following virtual conferences in April.
- Needham Healthcare Conference 2022
- Company Presentation by Chief Financial Officer Jeff Trigilio,
Wednesday, April 13, 2022, 8:00 a.m. EDT
- Canaccord Genuity Horizons in Oncology Virtual Conference
- Fireside Chat with Chief Executive Officer Nadim Ahmed,
Thursday, April 14, 2022, 2:00 p.m. EDT
Live webcasts of the Needham conference presentation and
Canaccord Genuity conference fireside chat will be available via
the Events section of the Company’s investor relations website at
https://investors.cullinanoncology.com/news-events/events.
Management will also be participating in one-on-one investor
meetings. Investors interested in scheduling a meeting with
Cullinan’s management should contact their respective financial
institution representatives.
About Cullinan Oncology Cullinan Oncology, Inc.
(NASDAQ: CGEM) is a biopharmaceutical company dedicated to creating
new standards of care for patients with cancer. We innovate without
borders to find the most promising clinic-ready cancer therapies,
whether from our own discovery efforts or through exceptional
engagement with our academic and industry partners. Anchored in a
deep understanding of immuno-oncology and translational cancer
medicine, we leverage our scientific excellence in small molecules
and biologics to create differentiated ideas, identify unique
targets, and select the optimal modality to develop transformative
therapeutics across cancer indications. Powered by our novel
research model, we push conventional boundaries from candidate
selection to cancer therapeutic, applying rigorous early
experimentation to fast-track only the most promising assets to the
clinic and ultimately commercialization. As a result, our
diversified pipeline is strategically built with assets that
activate the immune system or inhibit key oncogenic drivers across
a wide range of modalities, each with the potential to be the best
or first in their class.
Our people possess deep scientific expertise, seek innovation
openly, and exercise creativity and urgency to deliver on our
promise to bring new therapeutic solutions to patients with cancer.
Learn more about our Company at www.cullinanoncology.com, and
follow us on LinkedIn and Twitter.
Contacts: Investor Relations Chad Messer+1
203.464.8900cmesser@cullinanoncology.com
MediaRose Weldon+1 215.801.7644rweldon@cullinanoncology.com
Cullinan Therapeutics (NASDAQ:CGEM)
Historical Stock Chart
From Jun 2024 to Jul 2024
Cullinan Therapeutics (NASDAQ:CGEM)
Historical Stock Chart
From Jul 2023 to Jul 2024